Can simple brain games help track Huntington's?
NCT ID NCT06546488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two thinking and memory tests—the Coding Test and the SAGE test—to see if they can help doctors better understand and track Huntington's disease. Researchers will compare these tests with standard ones used in clinics. The goal is to find easier or better ways to screen people with Huntington's and measure how the disease progresses. About 76 adults with a confirmed Huntington's diagnosis will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 76 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Huntington disease patients with a clinical diagnosis.
- Ages
-
30 to 65 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form. 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40. 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4. 4. Vision and hearing sufficient for compliance with tests. 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form. Exclusion Criteria: 1. Age of symptom onset less than 19 years old or greater than 60 years old. 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant. 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure). 4. Subjects who are pregnant or breast feeding 5. Subjects with a history of a learning disability. 6. Subjects who are unable to provide consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Huntington disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Ohio State University Wexner Medical Center
RECRUITINGColumbus, Ohio, 43221, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody calm the immune attack in Huntington's disease?
- Can a single molecule quiet the genetic chaos behind three brain diseases?
- Can a genetic 'Patch' fix Huntington's disease? lab test aims to find out
- Could a brain disease change behavior years before diagnosis?
- Scientists decode gait signatures to spot brain diseases
- Can a One-Page guide spark better End-of-Life talks for dementia patients?